Replies to post #28615 on RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

I think if someone like Baxter wanted to co-develop RD with us and fund a good bit of it we'd have a much higher stock, and eventually worth say at least $600-700 million pre-2009 pipes about $10 or so. I think they had SGP interested in RD as well, way back when in 2008 summer some interest in a pro-drug for RD combining cx-???? with Oxycontin or another pain drug. The effect of Ampakines on the RD opens up a whole cadre of things these drugs might do, yet here we are.

[gfp927z]

Jerry, So you think the most likely deal involves RD plus SA, with the final terms depending upon the SA results? That would make sense on multiple levels.

However, one problem that good SA results creates is that the partner may then want CX-1739 included in the deal. But including CX-1739 would mean a whole other ballgame upfronts-wise, since losing CX-1739 prevents Cortex from quickly pursuing ADHD inhouse, since the backup compound CX-2007 is still preclinical.

On the other hand, if SA results are mediocre/bad, then things are more straightforward, and CX-1739 stays out of the RD/SA deal and is available for the inhouse ADHD trial.

I wonder though, if a pharma can really base very much on results for 6 or 7 SA patients anyway? (2 of which will likely be placebo patients) Could such a tiny trial justify upfronts high enough for Cortex to part with CX-1739?

So I'm not putting much weight on SA either way. The trial is too small for a pharma to base a strong decision on, and in that case an RD/SA deal would have to be primarily based on the pharma's interest in RD, with SA being a modest bonus indication. As such, the pharma would presumably be satisfied getting one of Cortex's backup compounds for SA, or alternately they could just use the oral version of CX-1942 for SA (the advanced IV prodrug for RD).

Perhaps Neuro will comment on the topic.